news Cancer-promoting gene a potential target for pulmonary hypertension 22 December 2021 | By Anna Begley (Drug Target Review) The new study identified PDZ-binding kinase (PBK) as a promising target for pulmonary hypertension and assessed two PBK inhibitors.
news Brain recordings could improve deep brain stimulation therapy for OCD 21 December 2021 | By Anna Begley (Drug Target Review) Scientists captured more than 1,000 hours of brain recordings from obsessive compulsive disorder (OCD) patients and uncovered candidate neurological signatures.
news Nanotechnology boosts immune response at tumour site in mice 20 December 2021 | By Anna Begley (Drug Target Review) The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
news Experimental gel promotes arteriovenous fistula (AVF) formation in rodents 17 December 2021 | By Anna Begley (Drug Target Review) The self-assembling, nanomatrix gel may represent the first effective therapy to promote healthy arteriovenous fistula (AVF) maturation in kidney disease patients.
news Common antioxidant reduces osteoarthritis markers in knee cartilage cells 16 December 2021 | By Anna Begley (Drug Target Review) Gallic acid was found to decrease arthritis inflammation markers and improve the production of desired proteins in arthritic knee cells.
news New platform screens for specific class of coronavirus antiviral compounds 15 December 2021 | By Anna Begley (Drug Target Review) Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.
news Mechanism that causes ALS nerve destruction unveiled for first time 15 December 2021 | By Anna Begley (Drug Target Review) The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
news Researchers investigate gene network to identify “cancer driver genes” 14 December 2021 | By Anna Begley (Drug Target Review) The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
news Transformable nanoparticles promise advances in tumour treatments 13 December 2021 | By Anna Begley (Drug Target Review) A new study provides an in-depth review on the designs and applications of morphology-transformable nanoparticles to improve cancer therapies.
news Three RNA-expression states may reveal cancer drug susceptibility 10 December 2021 | By Anna Begley (Drug Target Review) Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
news Scientists discover novel B cell that tempers autoimmunity 10 December 2021 | By Anna Begley (Drug Target Review) Infusions of purified IL-27 regulatory B cells (I27-Bregs) reduced symptoms in mouse models of multiple sclerosis and autoimmune uveitis.
news Experimental enzyme treatment protects mice from lethal anthrax infection 9 December 2021 | By Anna Begley (Drug Target Review) All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
news Scientists create first patient-specific zebrafish model for ACM 9 December 2021 | By Anna Begley (Drug Target Review) Researchers developed a patient-specific zebrafish model for arrhythmogenic cardiomyopathy (ACM) and tested istaroxime as a potential therapeutic.
news Scientists discover mechanism that links autism and intestinal inflammation 8 December 2021 | By Anna Begley (Drug Target Review) The new research shows how interleukin-17a (IL-17a) can alter the trajectory of immune system development and cause gut inflammation.
news Key mechanism reveals how SARS-CoV-2 evades our immune system 8 December 2021 | By Anna Begley (Drug Target Review) Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
